WO2011084098A1 - Process for making a metabotropic glutamate receptor positive allosteric modulator - 874 - Google Patents

Process for making a metabotropic glutamate receptor positive allosteric modulator - 874 Download PDF

Info

Publication number
WO2011084098A1
WO2011084098A1 PCT/SE2011/050002 SE2011050002W WO2011084098A1 WO 2011084098 A1 WO2011084098 A1 WO 2011084098A1 SE 2011050002 W SE2011050002 W SE 2011050002W WO 2011084098 A1 WO2011084098 A1 WO 2011084098A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
trifluoromethoxy
carboxylic acid
bromo
benzyl
Prior art date
Application number
PCT/SE2011/050002
Other languages
French (fr)
Inventor
Alistair Boyd
Mark Richard Fielding
James Gair Ford
Lianne Frodsham
Michael D Golden
Kevin William Leslie
Ben Mckeever-Abbas
Paula Tomlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2012007992A priority Critical patent/MX2012007992A/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to BRBR112012016786-3A priority patent/BR112012016786A2/en
Priority to US13/519,398 priority patent/US20130203995A1/en
Priority to AU2011203993A priority patent/AU2011203993A1/en
Priority to EP20110731990 priority patent/EP2521722B1/en
Priority to SG2012047528A priority patent/SG181958A1/en
Priority to DK11731990.5T priority patent/DK2521722T3/en
Priority to JP2012547983A priority patent/JP2013516462A/en
Priority to CA2786327A priority patent/CA2786327A1/en
Priority to CN2011800128476A priority patent/CN102791706A/en
Priority to RU2012134329/04A priority patent/RU2012134329A/en
Publication of WO2011084098A1 publication Critical patent/WO2011084098A1/en
Priority to IL220683A priority patent/IL220683A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to methods for the preparation of an mGluR2 positive allosteric modulator.
  • the metabotropic glutamate receptors constitute a family of GTP-binding- protein (G-protein) coupled receptors that are activated by glutamate, and have important roles in synaptic activity in the central nervous system, including neural plasticity, neural development and neurodegeneration.
  • Activation of mGluRs in intact mammalian neurons elicits one or more of the following responses: activation of phospholipase C; increases in phosphoinositide (PI) hydrolysis;
  • Group-I includes mGluRl and mGluR5, which activate phospholipase C and the generation of an intracellular calcium signal.
  • the Group-II mGluR2 and mGluR3
  • Group-Ill mGluR4, mGluR6, mGluR7, and mGluR8 mGluRs mediate an inhibition of adenylyl cyclase activity and cyclic AMP levels.
  • mGluR family receptors are implicated in a number of normal processes in the mammalian CNS, and are important targets for compounds for the treatment of a variety of neurological and psychiatric disorders. Activation of mGluRs is required for induction of hippocampal long-term potentiation and cerebellar long-term depression (Bashir et al, 1993, Nature, 363:347 ; Bortolotto et al, 1994, Nature, 368:740 ; Aiba et al, 1994, Cell, 79:365 ; Aiba et al, 1994, Cell, 79:377).
  • mGluR activation has been suggested to play a modulatory role in a variety of other normal processes including synaptic transmission, neuronal development, apoptotic neuronal death, synaptic plasticity, spatial learning, olfactory memory, central control of cardiac activity, waking, motor control and control of the vestibulo-ocular reflex (Nakanishi, 1994, Neuron, 13:1031; Pin et al., 1995, Neuropharmacology, supra; Knopfel et al., 1995, J. Med. Chem., 38: 1417).
  • the compound made by a process described herein may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compound. Still further, it will be understood by those of skill in the art that the compound may be made by varying, or modifying, the process described herein. Particularly, those of skill in the art will understand that, as examples, solvents, temperatures or specific reagents may be changed or varied and that such changes are within the scope of the present invention. Within the scope of the invention are also salts of the compound. Generally, pharmaceutically acceptable salts of compound made by the process of the present invention are obtained using standard procedures well known in the art.
  • the compound may be a pharmaceutically acceptable salt or a solvate thereof.
  • a pharmaceutically acceptable salt may be an acidic addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or /?-toluenesulphonate.
  • R A short chain alkyl group, for example, ethyl
  • the title compound may be prepared according to Scheme A, as follows.
  • Bromoacetonitrile (1.20 mol eq) may be charged to a cooled solution of tert-butyl piperazine-1- carboxylate (Ala) (1.00 mol eq) and tetramethylguanidine (1.45 mole eq) in tetrahydrofuran (3.6 rel vols).
  • Al tert-butyl piperazine-1- carboxylate
  • tetramethylguanidine 1.45 mole eq
  • tetrahydrofuran 3.6 rel vols
  • the organic solution may be concentrated by vacuum distillation before methanol (1.10 rel vols) is added and the mixture cooled.
  • Hydroxylamine hydrochloride (1.70 mol eq), tetramethylguanidine (1.70 mol eq) and water (0.25 mol eq) may be added, and the mixture heated.
  • the mixture may be charged with sodium chloride (0.15 rel wt) and allowed to separate into 2 phases.
  • the lower phase may be removed and back-extracted twice with 2- methyltetrahydrofuran (1.40 rel vols).
  • the combined organic phases may be mixed with heptane (8.0 rel vols), cooled, and seeded. The mixture may be held before cooling further and charging more heptane.
  • the title compound (A3a) may be recovered by filtration, washed once with cold water and twice with heptane and then dried under vacuum (69%).
  • the title compound may be prepared according to Scheme B, as follows.
  • a solution of 5- bromo-2-iodo-l,3-dimethyl-benzene (Bl) (1.0 mol eq) in methyl-tert-butyl ether (6.0 rel vols) may be added to iso-propylmagnesium chloride (2.0 mol eq) in methyl-tert-butyl ether (2.0 rel vols), maintaining ⁇ 0 °C.
  • Carbon dioxide gas may be added until reaction is shown to be complete.
  • 2N aqueous hydrochloric acid may be added (4 rel vols) to quench the reaction, the phases can be separated and the aqueous phase discarded.
  • the product may be extracted into 1M aqueous sodium hydroxide solution (6.5 rel vols), then washed with methyl tert-butyl ether (4 rel vols).
  • the title compound (B2) may be precipitated by the addition of 2N aq hydrochloric acid (4.5 rel vols) before being filtered, washed with water then heptane and dried to yield a white crystalline solid (85%).
  • the title compound may be prepared according to Scheme B, as follows.
  • a slurry of 4- bromo-2,6-dimethylbenzoic acid (B2) (1.0 mol eq), N-bromosuccinimide (2.5 mol eq) and benzoyl peroxide (0.1 mol eq) in chlorobenzene (10 rel vols) may be heated to >70 °C until the reaction is shown to be complete.
  • a solution of 40%> w/w aqueous sodium sulfite (4 rel.vol) may be added to the reaction mixture, the phases separated and the aqueous phase discarded.
  • the organic phase may be washed with saturated aqueous sodium bicarbonate (6 rel vol).
  • the chlorobenzene phase may be concentrated (to 3 rel vols) by vacuum distillation and
  • the title compound may be prepared according to Scheme B, as follows.
  • the title compound may be prepared according to Scheme B, as follows. 5-Bromo-7- methyl-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-isoindol-l-one (B5) (1.0 mol eq), zinc cyanide (0.6 mol eq), l,l '-bis(diphenylphosphino)ferrocene (0.012 mol eq),
  • the title compound may be prepared according to Scheme B, as follows. 7-M ethyl- 1- oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5-carbonitrile (B6) may be mixed with methanol (10 rel vols) and 49% aqueous potassium hydroxide (3.0 mol eq) and heated until reaction is complete. The mixture may be concentrated under vacuum to remove the methanol and then diluted with aq. hydrochloric acid to precipitate the product, which may be extracted with iso-propyl acetate. The organic phase may be concentrated to remove solvent, then triturated with heptane, filtered and dried to afford the title compound (B7) (85%).
  • the title compound may be prepared according to Scheme C, as follows. To a solution of ethyl-3-furoate (CI a) (1 mol eq) in ⁇ , ⁇ -dimethyl formamide (4 mol eq) may be added phosphoryl chloride (4 mol eq). The resulting solution may be heated to 60 °C until reaction is deemed complete. The reaction mixture may be then added to a solution of sodium carbonate (8.25 mol eq) in water (18 rel vols). Toluene (7 rel vols) may be added, and the phases separated. The organic phase may be concentrated (to 4.2 rel vols total volume) under atmospheric pressure. This will afford a 22.1% w/w solution of the title compound (C2a) as 3.5% w/w solution in toluene (73%).
  • the title compound may be prepared according to Scheme C by use of a flow reactor (for example, a 2-train Continuously Stirred Tank Reactor (CSTR)).
  • a CSTR may be fed with ethyl- 3-furoate (CI a) (1 mol eq), ⁇ , ⁇ -dimethyl formamide (3.833 mol eq) and phosphoryl chloride (4.167 mol eq).
  • the reaction temperature may be maintained at 105 °C, and the feed rates adjusted to yield a mean residence time of 2 hours.
  • the solution leaving the reactor may be quenched into a solution of potassium bicarbonate (8.33 mol eq) in water (3.13 L / g potassium carbonate).
  • Toluene (0.26 L / L water) may be added, and the phases separated.
  • the organic phase may be concentrated (by 3.2 volumes) via distillation under atmospheric pressure. This will afford a 22.4% w/w solution of the title compound (C2a) in toluene.
  • the title compound may be prepared according to Scheme C, as follows. To a 22. l%w/w solution of 5-formyl-furan-3-carboxylic acid ethyl ester (C2a) (1 mol eq) in toluene,
  • the title compound may be prepared according to Scheme C, as follows. Crotonoyl chloride (1.05 mol eq) may be added to a mixture of 5-[(4-trifluoromethoxy-benzylamino)- methyl]-furan-3-carboxylic acid ethyl ester hydrochloride (C3a) (1.0 mol eq), di- isopropylethylamine (2.5 mol eq) and toluene (10 rel vols) at ambient temperature. When the reaction is complete, the mixture may be washed with water (5 rel vols), concentrated (to 5 rel vols total volume) and heated to reflux for > 12 hours.
  • Crotonoyl chloride (1.05 mol eq) may be added to a mixture of 5-[(4-trifluoromethoxy-benzylamino)- methyl]-furan-3-carboxylic acid ethyl ester hydrochloride (C3a) (1.0 mol eq), di- is
  • Methanesulphonic acid (1.0 mol eq) may be added, and the reaction then heated to reflux under Dean & Stark conditions until reaction is deemed complete. The solution may be then washed with aqueous sodium hydroxide solution (5 rel vols) then water (5 rel vols). Heptane (10 rel vols) may be added, and the mixture cooled to permit crystallization to occur. The mixture may be filtered and the recovered solid dried to afford the title compound (C4a) as a white crystalline solid (73%).
  • the title compound may be prepared as according to Scheme C, as follows. 7-Methyl-l- oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5-carboxylic acid ethyl ester (C4a) may be mixed with 2-propanol (4 rel vols) and 49% aqueous potassium hydroxide (1.5 mol eq) and heated until reaction is complete. 36% w/w aqueous hydrochloric acid (2.00 mol eq), may be added, the reaction mixture cooled to ambient temperature and water (5 rel vols) added. The title compound (B7) may be recovered by filtration and dried (98%>).
  • Example 12a Preparation of 4- ⁇ 5-[7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihvdro- lH-isoindol-5- ⁇ '-/ 1 ,2, 41oxadiazol-3-ylmethyl ⁇ -piperazine-l-carboxylic acid tert-butyl ester
  • the title compound may be prepared according to Scheme C, as follows. 4-(N- Hydroxycarbamimidoylmethyl)-piperazine-l-carboxylic acid tert-butyl ester (A3a) (1.0 mol eq) and 7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5-carboxylic acid ethyl ester (C4a) (1.0 mol eq) can be mixed in acetonitrile (14 rel vols) at 60 °C. Sodium ethoxide (0.2 mols) may be added over 20 mins and the reaction held at 60 °C until complete. Water (10 rel vols) may be added and the mixture cooled to ambient temperature. The title compound (Dla) may be recovered by filtration and washed with water before being dried
  • Example 12b Preparation of 4- ⁇ 5-[7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihvdro- lH-isoindol-5-yl]-[l,2, 4] oxadiazol-3-ylmethyl ⁇ -piperazine-l -carboxylic acid tert-butyl ester
  • the title compound may be prepared according to Scheme C, as follows.
  • a slurry of 7- methyl-l-oxo-2-[4-(trifluoromethoxy)-benzyl]-2,3-dihydro-lH-isoindole-5-carboxylic acid (B7) (1.00 mol eq) in toluene (8.0 rel vols) may be heated and thionyl chloride (1.50 mol eq) added. When the reaction is complete, excess thionyl chloride and toluene can be removed by atmospheric distillation.
  • This solution may be added to a slurry of 4-(N- hydroxycarbamimidoylmethyl)-piperazine-l-carboxylic acid tert-butyl ester (A3 a) (1.1 mol eq) and potassium carbonate (1.25 mol eq) in 2-methyl tetrahydrofuran (19.0 rel vols).
  • Tetrabutylammonium fluoride (1.0 mol eq) in tetrahydrofuran (0.5 rel vols) may be charged and the contents heated until the cyclization is complete. After cooling the organic phase may be washed with water before being concentrated by distillation. Methyl-t-butyl ether may be added to induce crystallization. After cooling, the title compound (Dla) may be recovered by filtration, washed with methyl-t-butyl ether and dried to constant weight in a vacuum oven.
  • Example 13 Preparation of 7-methyl-5-(3-piperazin-l-ylmethyl-[ 1 ,2,4] oxadiazol-5-yl)-2-(4- trifluoromethoxy-benzyl)-2,3-dihvdro-isoindol-l-one as a methanesulphonate (D2)
  • reaction mixture After addition of further water (10 mL), the reaction mixture may be held at 85 °C until reaction is complete. The reaction mixture may be cooled to 65-70 °C before conducting a screening filtration into a crystallizer. The reaction vessel and the line can be rinsed into the crystalliser with hot (80 °C) 1 -butanol (1 x 200 mL). The resulting reaction mixture may be then held at 85 °C before addition of 1 -butanol (800 mL), cooling to 78 °C and seeding with (D2) (0.1 g, 1% w/w).
  • reaction mixture can then be cooled to 15 °C and temperature-cycled to 65-70 °C twice, before filtration to afford the title compound (D2) which may be washed with 1- butanol (2 x 200 mL) before drying under vacuum to afford the title compound as a white solid (87.38 g, 88.0% yield).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Processes for making 7-methyl-5-(3piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one

Description

PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE
ALLOSTERIC MODULATOR - 874
BACKGROUND
The present invention relates to methods for the preparation of an mGluR2 positive allosteric modulator.
The metabotropic glutamate receptors (mGluR) constitute a family of GTP-binding- protein (G-protein) coupled receptors that are activated by glutamate, and have important roles in synaptic activity in the central nervous system, including neural plasticity, neural development and neurodegeneration.
Activation of mGluRs in intact mammalian neurons elicits one or more of the following responses: activation of phospholipase C; increases in phosphoinositide (PI) hydrolysis;
intracellular calcium release; activation of phospholipase D; activation or inhibition of adenyl cyclase; increases or decreases in the formation of cyclic adenosine monophosphate (cAMP); activation of guanylyl cyclase; increases in the formation of cyclic guanosine monophosphate (cGMP); activation of phospholipase A2; increases in arachidonic acid release; and increases or decreases in the activity of voltage- and ligand-gated ion channels (Schoepp et al, 1993, Trends Pharmacol. Sci., 14: 13 ; Schoepp, 1994, Neurochem. Int., 24:439; Pin et al, 1995,
Neuropharmacology 34: 1; Bordi & Ugolini, 1999, Prog. Neurobiol. 59:55).
Eight mGluR subtypes have been identified, which are divided into three groups based upon primary sequence similarity, signal transduction linkages, and pharmacological profile. Group-I includes mGluRl and mGluR5, which activate phospholipase C and the generation of an intracellular calcium signal. The Group-II (mGluR2 and mGluR3) and Group-Ill (mGluR4, mGluR6, mGluR7, and mGluR8) mGluRs mediate an inhibition of adenylyl cyclase activity and cyclic AMP levels. For a review, see Pin et al, 1999, Eur. J. Pharmacol, 375:277-294.
Activity of mGluR family receptors are implicated in a number of normal processes in the mammalian CNS, and are important targets for compounds for the treatment of a variety of neurological and psychiatric disorders. Activation of mGluRs is required for induction of hippocampal long-term potentiation and cerebellar long-term depression (Bashir et al, 1993, Nature, 363:347 ; Bortolotto et al, 1994, Nature, 368:740 ; Aiba et al, 1994, Cell, 79:365 ; Aiba et al, 1994, Cell, 79:377). A role for mGluR activation in nociception and analgesia also has been demonstrated (Meller et al., 1993, Neuroreport, 4: 879; Bordi & Ugolini, 1999, Brain Res., 871 :223). In addition, mGluR activation has been suggested to play a modulatory role in a variety of other normal processes including synaptic transmission, neuronal development, apoptotic neuronal death, synaptic plasticity, spatial learning, olfactory memory, central control of cardiac activity, waking, motor control and control of the vestibulo-ocular reflex (Nakanishi, 1994, Neuron, 13:1031; Pin et al., 1995, Neuropharmacology, supra; Knopfel et al., 1995, J. Med. Chem., 38: 1417).
Recent advances in the elucidation of the neurophysiological roles of mGluRs have established these receptors as promising drug targets in the therapy of acute and chronic neurological and psychiatric disorders and chronic and acute pain disorders. Because of the physiological and pathophysiological significance of the mGluRs, there is a need for new drugs and compounds that can modulate mGluR function.
DESCRIPTION OF THE INVENTION
The schemes and processes described herein illustrate the preparation of 7-methyl-5-(3- piperazin- 1 -ylmethyl-[ 1 ,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol- 1-one, having the structure below:
Figure imgf000003_0001
It will be understood by those of skill in the art that the compound made by a process described herein may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compound. Still further, it will be understood by those of skill in the art that the compound may be made by varying, or modifying, the process described herein. Particularly, those of skill in the art will understand that, as examples, solvents, temperatures or specific reagents may be changed or varied and that such changes are within the scope of the present invention. Within the scope of the invention are also salts of the compound. Generally, pharmaceutically acceptable salts of compound made by the process of the present invention are obtained using standard procedures well known in the art.
In one embodiment of the present invention, the compound may be a pharmaceutically acceptable salt or a solvate thereof. Particularly, a pharmaceutically acceptable salt may be an acidic addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or /?-toluenesulphonate.
The invention is illustrated by way of the following schemes and examples, which describe several embodiments of the process of the invention. The synthetic schemes and the synthetic procedures provided herein are provided by way of illustration and are not to be construed as limiting the invention. It will be clear to those skilled in the art that the compound or its intermediates may be prepared by modifications of the processes described.
Scheme A
Figure imgf000004_0001
Figure imgf000004_0002
Scheme
Figure imgf000005_0001
(D1)
Scheme D
Figure imgf000005_0002
Definitions:
The following definitions are used in the schemes and descriptions herein:
NB from schemes, please check and correct where necessary
"PG" - Protecting Group, for example a BOC group
"BrCH2CN" - Bromoacetonitrile
"NH2OH" - Hydoxylamine
"iPrMgCl" - Iso-propylmagnesium chloride
"NBS" - N-Bromosuccinimide
"(PhC(CO)0)2" - Benzoyl peroxide
"AlMe3" - Trimethylaluminium
"Ms20" - Methanesulphonyl anhydride
"NaOPt" - Sodium t-amylate
"ZnCN2" - Zinc cyanide
"R" - A short chain alkyl group, for example, ethyl
"POCI3" - Phosphorous oxychloride
"DMF" - Dimethyl formamide
"NaBH4 M - Sodium borohydride
"SOCl2" - Thionyl Chloride
"NaOEt" - Sodium ethoxide
"TBAF" - Tetrabutylammonium fluoride
"MsOH" - Methane sulfonic acid
"rel vol" or "rel vols" - Relative volumes
For all the Examples and processes described herein amounts of materials, solvents, volumes, temperatures and times are exemplary and are not to be taken as limiting the manner in which such reactions may be performed or the scope of the invention. Variations in amounts of materials, solvents, volumes, temperatures and times may be made while carrying out the processes described and while practicing the invention described herein.
Example 1: Preparation of 4-(N-hvdroxycarbamimidoylmethv1)-piperazine-l-carboxylic acid tert-butyl ester (A3a)
Figure imgf000007_0001
(A3a)
The title compound may be prepared according to Scheme A, as follows.
Bromoacetonitrile (1.20 mol eq) may be charged to a cooled solution of tert-butyl piperazine-1- carboxylate (Ala) (1.00 mol eq) and tetramethylguanidine (1.45 mole eq) in tetrahydrofuran (3.6 rel vols). When the reaction is complete the mixture may be warmed, 2-methyltetrahydrofuran (5.0 rel vols) added and then washed with water (1.50 rel vols). The organic solution may be concentrated by vacuum distillation before methanol (1.10 rel vols) is added and the mixture cooled. Hydroxylamine hydrochloride (1.70 mol eq), tetramethylguanidine (1.70 mol eq) and water (0.25 mol eq) may be added, and the mixture heated. When the reaction is complete the mixture may be charged with sodium chloride (0.15 rel wt) and allowed to separate into 2 phases. The lower phase may be removed and back-extracted twice with 2- methyltetrahydrofuran (1.40 rel vols). The combined organic phases may be mixed with heptane (8.0 rel vols), cooled, and seeded. The mixture may be held before cooling further and charging more heptane. The title compound (A3a) may be recovered by filtration, washed once with cold water and twice with heptane and then dried under vacuum (69%).
1H NMR (400MHz, CDC13) δ: 1.46 (s, 9H), 2.42 (m, 4H), 3.00 (s, 2H), 3.43 (m, 4H), 5.10 (s, 2H). Example 2: Preparation of 4-bromo-2,6-dimethylbenzoic acid (B2)
Figure imgf000007_0002
(B2)
The title compound may be prepared according to Scheme B, as follows. A solution of 5- bromo-2-iodo-l,3-dimethyl-benzene (Bl) (1.0 mol eq) in methyl-tert-butyl ether (6.0 rel vols) may be added to iso-propylmagnesium chloride (2.0 mol eq) in methyl-tert-butyl ether (2.0 rel vols), maintaining < 0 °C. Carbon dioxide gas may be added until reaction is shown to be complete. 2N aqueous hydrochloric acid may be added (4 rel vols) to quench the reaction, the phases can be separated and the aqueous phase discarded. The product may be extracted into 1M aqueous sodium hydroxide solution (6.5 rel vols), then washed with methyl tert-butyl ether (4 rel vols). The title compound (B2) may be precipitated by the addition of 2N aq hydrochloric acid (4.5 rel vols) before being filtered, washed with water then heptane and dried to yield a white crystalline solid (85%).
1H NMR (400 MHz, CDC13) δΗ 2.28 (6 H, s), 7.35 (2 H, s), 13.30 (1H, s). Example 3: Preparation of 5-bromo-7-methyl-3H-isobenzofuran-l-one (B3)
Figure imgf000008_0001
(B3)
The title compound may be prepared according to Scheme B, as follows. A slurry of 4- bromo-2,6-dimethylbenzoic acid (B2) (1.0 mol eq), N-bromosuccinimide (2.5 mol eq) and benzoyl peroxide (0.1 mol eq) in chlorobenzene (10 rel vols) may be heated to >70 °C until the reaction is shown to be complete. A solution of 40%> w/w aqueous sodium sulfite (4 rel.vol) may be added to the reaction mixture, the phases separated and the aqueous phase discarded. The organic phase may be washed with saturated aqueous sodium bicarbonate (6 rel vol). The chlorobenzene phase may be concentrated (to 3 rel vols) by vacuum distillation and
dimethylacetamide added (2.5 rel vols), before adding this solution to a mixture of sodium borohydride (1.6 mol eq) in dimethylacetamide (3 rel vol). The mixture may be stirred until the reaction is shown to be complete. The mixture may be then quenched with a solution of 36% w/w hydrogen chloride (2.5 mol eq) in water (3.5 rel vol). Removing solvent by vacuum distillation will precipitate the title compound (B3) as a white crystalline solid, which may be filtered and dried (59%).
1H NMR (400 MHz, DMSO) δΗ 2.57 (s, 3H), 5.32 (s, 2H), 7.60 (s, 1H), 7.73 (s, 1H). Example 4: Preparation of 4-bromo-2-hvdroxymethyl-6-methyl-N-(4-trifluoromethoxy-benzyl)- benzamide (B4)
Figure imgf000009_0001
(B4)
The title compound may be prepared according to Scheme B, as follows.
4-(Trifluoromethoxy)-benzylamine (1.2 mol eq) may be added to a solution of 5-bromo-7- methyl-3H-isobenzofuran-l-one (B3) (1.0 mol eq) in 2-methyltetrahydrofuran (10 rel vols) and inerted. Trimethylaluminium (1.2 mol eq) may be added and the resulting solution heated to >40 °C until the reaction is complete. The organic solution may be then added to a cooled solution of potassium sodium tartrate (1.5 mol eq) in water (3 rel vols) and stirred. This biphasic mixture may be separated, and the aqueous phase discarded. The organic phase may be washed with water (3.33 rel vols), then nonane (3 rel vols) may be added and the
2-methyltetrahydrofuran removed by vacuum distillation to crystallise (B4) as a white crystalline solid, which may be filtered, washed with nonane and dried (73.5%).
1H NMR (400 MHz, DMSO) δΗ 2.19 (s, 3H), 4.44 (dd, 4H, 13.4 Hz, 5.78 Hz), 5.33 (t, 1H, 5.76 Hz), 7.34 (s, 1H), 7.35 (s, 2H), 7.47 (s, 1H), 7.49 (s, 2H), 8.85 (t, 1H, 5.76 Hz).
Example 5: Preparation of 5-bromo-7 -methyl-2-(4-trifluoromethoxy-benzyl)-2 ,3-dihvdro- isoindol-l-one (B5)
Figure imgf000009_0002
(B5) The title compound may be prepared according to Scheme B, as follows. Triethylamine (1.4 mol eq) may be added to 4-bromo-2-hydroxymethyl-6-methyl-N-(4-trifluoromethoxy- benzyl)-benzamide (B4) (1.0 mol eq) in 2-methyltetrahydrofuran (5 rel vols). Methanesulphonyl chloride (1.1 mol eq) may be added to this solution, maintaining <5 °C. This may be stirred until the reaction is shown to be complete. Sodium tert-amylate (2.5 mol eq) may be added while maintaining the temperature at <5 °C and the reaction stirred until reaction is completed. Water (10 rel vols) may be added and the resulting biphasic mixture separated, discarding the aqueous phase. 2.7 M aqueous hydrochloric acid (4 rel vols) may be added and the phases separated, discarding the aqueous phase. The organic phase may be concentrated to dryness and the resulting wax recrystallised in heptane (4 rel vols). Filtering, washing with heptane and drying, will afford the title compound (B5) as a white solid (77%).
1H NMR (400 MHz, DMSO) δΗ 2.64 (s, 3H), 4.33 (s, 2H), 4.73 (s, 2H), 7.34 (d, 2H, 8.40Hz), 7.42 (d, 2H, 8.40Hz), 7.47 (s, 1H), 7.59 (s, 1H). Example 6: Preparation of 7-methyl-l -oxo-2-(4-trifluoromethoxy-benzyl)-2 ,3-dihvdro-l Ή- isoindole-5-carbonitrile
Figure imgf000010_0001
(B6)
The title compound may be prepared according to Scheme B, as follows. 5-Bromo-7- methyl-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-isoindol-l-one (B5) (1.0 mol eq), zinc cyanide (0.6 mol eq), l,l '-bis(diphenylphosphino)ferrocene (0.012 mol eq),
tris(dibenzylideneacetone)-dipalladium (0) (0.005 mol eq), dimethylformamide (5 rel vols) and water (0.25 mol eq) can be charged to a vessel and thoroughly inerted with nitrogen before heating to >90 °C until the reaction is complete. The reaction may be cooled and t-methyl butyl ether (13 rel vols) added with subsequent filtration. The organic phase obtained may be washed twice with 8.75% w/w aqueous ammonium hydroxide (14 rel vols). Heptane (14 rel vols) may be added to crystallize title compound (B6). Washing with a 9: 1 heptane/MTBE mix and drying will afford the title compound (B6) as a brown solid (40%>). 1H NMR (400 MHz, DMSO) δΗ 2.69 (d, 3H), 4.41 (s, 2H), 4.76 (s, 2H), 7.34 (s, 1H), 7.36 (s, 1H), 7.42 (s, 1H), 7.44 (s, 1H), 7.74 (s, 1H), 7.86 (s, 1H).
Example 7: Preparation of 7 -meth\l-l-oxo-2-(4-trifluoromethoxy-benzyl)-2 -di vdro-lH- isoindole-5-carboxylic acid (B7)
Figure imgf000011_0001
(B7)
The title compound may be prepared according to Scheme B, as follows. 7-M ethyl- 1- oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5-carbonitrile (B6) may be mixed with methanol (10 rel vols) and 49% aqueous potassium hydroxide (3.0 mol eq) and heated until reaction is complete. The mixture may be concentrated under vacuum to remove the methanol and then diluted with aq. hydrochloric acid to precipitate the product, which may be extracted with iso-propyl acetate. The organic phase may be concentrated to remove solvent, then triturated with heptane, filtered and dried to afford the title compound (B7) (85%).
1H NMR (400MHz, DMSO) δ: 2.71 (s, 3H), 4.42 (s, 2H), 4.77 (s, 2H), 7.35 (d, 2H, 8.73Hz), 7.43 (d, 2H, 8.73Hz), 7.81 (s, 1H), 7.91 (s, 1H), 13.19 (s, 1H, br).
Example 8a: Preparation of 5-formyl-furan-3-carboxylic acid ethyl ester (C2a)
Figure imgf000011_0002
(C2a)
The title compound may be prepared according to Scheme C, as follows. To a solution of ethyl-3-furoate (CI a) (1 mol eq) in Ν,Ν-dimethyl formamide (4 mol eq) may be added phosphoryl chloride (4 mol eq). The resulting solution may be heated to 60 °C until reaction is deemed complete. The reaction mixture may be then added to a solution of sodium carbonate (8.25 mol eq) in water (18 rel vols). Toluene (7 rel vols) may be added, and the phases separated. The organic phase may be concentrated (to 4.2 rel vols total volume) under atmospheric pressure. This will afford a 22.1% w/w solution of the title compound (C2a) as 3.5% w/w solution in toluene (73%).
1H NMR (400 MHz, CDC13) δΗ 1.37 (3 H, t, 7.2Hz), 4.33 (2 H, q, 7.2Hz), 7.54 (1 H, m), 8.22 H, m) and 9.69 (1 H, m).
Example 8b: Preparation of 5-formyl-furan-3-carboxylic acid ethyl ester (C2a)
The title compound may be prepared according to Scheme C by use of a flow reactor (for example, a 2-train Continuously Stirred Tank Reactor (CSTR)). A CSTR may be fed with ethyl- 3-furoate (CI a) (1 mol eq), Ν,Ν-dimethyl formamide (3.833 mol eq) and phosphoryl chloride (4.167 mol eq). The reaction temperature may be maintained at 105 °C, and the feed rates adjusted to yield a mean residence time of 2 hours. The solution leaving the reactor may be quenched into a solution of potassium bicarbonate (8.33 mol eq) in water (3.13 L / g potassium carbonate). Toluene (0.26 L / L water) may be added, and the phases separated. The organic phase may be concentrated (by 3.2 volumes) via distillation under atmospheric pressure. This will afford a 22.4% w/w solution of the title compound (C2a) in toluene.
1H NMR (400 MHz, CDC13) δΗ 1.37 (3 H, t, 7.2Hz), 4.33 (2 H, q, 7.2Hz), 7.54 (1 H, m), 8.22 (1 H, m) and 9.69 (1 H, m). Example 9: Preparation of 5-[ (4-trifluoromethoxy-benzylamino)-methyll -furan-3-carboxylic acid ethyl ester hydrochloride (C3a)
Figure imgf000012_0001
(C3a)
The title compound may be prepared according to Scheme C, as follows. To a 22. l%w/w solution of 5-formyl-furan-3-carboxylic acid ethyl ester (C2a) (1 mol eq) in toluene,
4-(trifluoromethoxy)-benzylamine (1.1 mol eq) may be added, and the reaction stirred until the reaction is complete. Sodium borohydride (1.25 mol eq) may be added and the resulting slurry cooled to >-5 °C. Ethanol (16.0 rel.vol.) may be added and the resulting solution quenched with aqueous hydrochloric acid (3.0 mol eq) to crystallise the title compound (C3a). This slurry may be heated to >60 °C and then cooled to improve the crystal form. Filtering and washing with toluene and then aqueous ethanol will afford the title compound (C3a) as a crystalline white solid (85%).
1H NMR (400MHz, DMSO) δΗ 1.28 (3 H, t), 4.24 (6 H, m), 6.97 (1 H, d), 7.44 (1 H, d), 7.70 (1 H, d), 8.46 (1 H, d).
Example 10: Preparation of 7-methyl-l -oxo-2-(4-trifluoromethoxy-benzyl)-2 ,3-dihvdro-l Ή- isoindole-5-carboxylic acid ethyl ester (C4a)
Figure imgf000013_0001
(C4a)
The title compound may be prepared according to Scheme C, as follows. Crotonoyl chloride (1.05 mol eq) may be added to a mixture of 5-[(4-trifluoromethoxy-benzylamino)- methyl]-furan-3-carboxylic acid ethyl ester hydrochloride (C3a) (1.0 mol eq), di- isopropylethylamine (2.5 mol eq) and toluene (10 rel vols) at ambient temperature. When the reaction is complete, the mixture may be washed with water (5 rel vols), concentrated (to 5 rel vols total volume) and heated to reflux for > 12 hours. Methanesulphonic acid (1.0 mol eq) may be added, and the reaction then heated to reflux under Dean & Stark conditions until reaction is deemed complete. The solution may be then washed with aqueous sodium hydroxide solution (5 rel vols) then water (5 rel vols). Heptane (10 rel vols) may be added, and the mixture cooled to permit crystallization to occur. The mixture may be filtered and the recovered solid dried to afford the title compound (C4a) as a white crystalline solid (73%).
1H NMR (400MHz, CDC13) δ: 1.40 (t, 3H, 7.12Hz), 2.81 (s, 3H), 4.27 (s, 2H), 4.39 (q, 2H, 7.12Hz), 4.78 (s, 2H), 7.18 (d, 2H, 8.60Hz), 7.35 (d, 2H, 8.19Hz), 7.87 (s, 1H), 7.90 (s, 1H).
Example 11: Preparation of 7-methyl-l-oxo-2-[4-(trifluoromethoxy)-benzyl]-2,3-dihvdro-lH- isoindole-5-carboxylic acid (B7)
Figure imgf000014_0001
(B7)
The title compound may be prepared as according to Scheme C, as follows. 7-Methyl-l- oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5-carboxylic acid ethyl ester (C4a) may be mixed with 2-propanol (4 rel vols) and 49% aqueous potassium hydroxide (1.5 mol eq) and heated until reaction is complete. 36% w/w aqueous hydrochloric acid (2.00 mol eq), may be added, the reaction mixture cooled to ambient temperature and water (5 rel vols) added. The title compound (B7) may be recovered by filtration and dried (98%>).
1H NMR (400MHz, DMSO) δ: 2.71 (s, 3H), 4.42 (s, 2H), 4.77 (s, 2H), 7.35 (d, 2H, 8.73Hz), 7.43 (d, 2H, 8.73Hz), 7.81 (s, 1H), 7.91 (s, 1H), 13.19 (s, 1H, br).
Example 12a: Preparation of 4-{5-[7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihvdro- lH-isoindol-5-νΓΐ '-/ 1 ,2, 41oxadiazol-3-ylmethyl}-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000014_0002
(Dla)
The title compound may be prepared according to Scheme C, as follows. 4-(N- Hydroxycarbamimidoylmethyl)-piperazine-l-carboxylic acid tert-butyl ester (A3a) (1.0 mol eq) and 7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5-carboxylic acid ethyl ester (C4a) (1.0 mol eq) can be mixed in acetonitrile (14 rel vols) at 60 °C. Sodium ethoxide (0.2 mols) may be added over 20 mins and the reaction held at 60 °C until complete. Water (10 rel vols) may be added and the mixture cooled to ambient temperature. The title compound (Dla) may be recovered by filtration and washed with water before being dried
(84%). 1H NMR (400MHz, CDC13) δ: 1.46 (9 H, s), 2.58 (4 H, m), 2.84 (3 H, s), 3.50 (4 H, m), 3.79 (2 H, s), 4.33 (2 H, s), 4.81 (2 H, s), 7.20 (2 H, m), 7.36 (2 H, m), 7.99 (1 H, s), 8.04 (1 H, s).
Example 12b: Preparation of 4-{5-[7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihvdro- lH-isoindol-5-yl]-[l,2, 4] oxadiazol-3-ylmethyl}-piperazine-l -carboxylic acid tert-butyl ester
(Dla)
The title compound may be prepared according to Scheme C, as follows. A slurry of 7- methyl-l-oxo-2-[4-(trifluoromethoxy)-benzyl]-2,3-dihydro-lH-isoindole-5-carboxylic acid (B7) (1.00 mol eq) in toluene (8.0 rel vols) may be heated and thionyl chloride (1.50 mol eq) added. When the reaction is complete, excess thionyl chloride and toluene can be removed by atmospheric distillation. This solution may be added to a slurry of 4-(N- hydroxycarbamimidoylmethyl)-piperazine-l-carboxylic acid tert-butyl ester (A3 a) (1.1 mol eq) and potassium carbonate (1.25 mol eq) in 2-methyl tetrahydrofuran (19.0 rel vols).
Tetrabutylammonium fluoride (1.0 mol eq) in tetrahydrofuran (0.5 rel vols) may be charged and the contents heated until the cyclization is complete. After cooling the organic phase may be washed with water before being concentrated by distillation. Methyl-t-butyl ether may be added to induce crystallization. After cooling, the title compound (Dla) may be recovered by filtration, washed with methyl-t-butyl ether and dried to constant weight in a vacuum oven.
1H NMR (400MHz, CDC13) δ: 1.46 (9 H, s), 2.58 (4 H, m), 2.84 (3 H, s), 3.50 (4 H, m), 3.79 (2 H, s), 4.33 (2 H, s), 4.81 (2 H, s), 7.20 (2 H, m), 7.36 (2 H, m), 7.99 (1 H, s), 8.04 (1 H, s).
Example 13: Preparation of 7-methyl-5-(3-piperazin-l-ylmethyl-[ 1 ,2,4] oxadiazol-5-yl)-2-(4- trifluoromethoxy-benzyl)-2,3-dihvdro-isoindol-l-one as a methanesulphonate (D2)
Figure imgf000015_0001
(D2) The title compound may be prepared according to Scheme D, as follows. To a solution of 4-{5-[7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindol-5-yl]- [l,2,4]oxadiazol-3-ylmethyl}-piperazine-l-carboxylic acid tert-butyl ester (Dla) (0.170 mol) in a mixture of 1 -butanol (250 mL) and water (30 mL) at 85 °C may be added methanesulfonic acid (0.187 mol). After addition of further water (10 mL), the reaction mixture may be held at 85 °C until reaction is complete. The reaction mixture may be cooled to 65-70 °C before conducting a screening filtration into a crystallizer. The reaction vessel and the line can be rinsed into the crystalliser with hot (80 °C) 1 -butanol (1 x 200 mL). The resulting reaction mixture may be then held at 85 °C before addition of 1 -butanol (800 mL), cooling to 78 °C and seeding with (D2) (0.1 g, 1% w/w). The reaction mixture can then be cooled to 15 °C and temperature-cycled to 65-70 °C twice, before filtration to afford the title compound (D2) which may be washed with 1- butanol (2 x 200 mL) before drying under vacuum to afford the title compound as a white solid (87.38 g, 88.0% yield).
1H NMR (400MHz, DMSO) δ: 2.36 (3 H, s), 2.81 (4 H, m), 3.15 (4 H, m), 3.91 (2 H, s), 4.46 (2 H, s), 4.78 (2 H, s), 7.37 (2 H, m), 7.45 (2 H, m), 8.00 (1 H, m), 8.12 (1 H, m) and 8.59 (1H, br s).

Claims

Claims:
Claim 1 A process for preparing 7-methyl-5-(3-piperazin- 1 -ylmethyl-[ 1 ,2,4]oxadiazol-5- yl)-2-(4-trifluoromethoxybenzyl -2,3-dihydroisoindol-l-one, having the structure below:
Figure imgf000017_0001
or an acid salt thereof, the process comprising:
reacting tert-butyl piperazine-l-carboxylate with bromoacetonitrile, in an organic solvent in the presence of a base and subsequent reaction with hydroxylamine or an acid salt thereof to form 4-(N-hydroxycarbamimidoylmethyl)-piperazine-l-carboxylic acid tert-butyl ester;
reacting 5 -bromo-2-iodo- 1,3 -dimethyl-benzene in an ether solvent with a Grignard reagent and carbon dioxide gas to form 4-bromo-2,6-dimethylbenzoic acid;
heating 4-bromo-2,6-dimethylbenzoic acid with N-bromosuccinimide and a radical initiator in an organic solvent and subsequent reduction of over-brominated products with a reducing agent to form 5-bromo-7-methyl-3H-isobenzofuran-l-one;
heating 5 -bromo-7-methyl-3H-isobenzofuran- 1 -one with
4- (trifluoromethoxy)-benzylamine in an anhydrous solvent with trimethylaluminium to form 4- bromo-2-hydroxymethyl-6-methyl-N-(4-trifluoromethoxy-benzyl)-benzamide;
reacting 4-bromo-2-hydroxymethyl-6-methyl-N-(4-trifluoromethoxy-benzyl)-benzamide with methanesulphonyl chloride and a base in an organic solvent to form 5-bromo-7-methyl-2- (4-trifluoromethoxy-benzyl)-2,3 -dihydro-isoindol- 1 -one;
heating 5 -bromo-7-methyl-2-(4-trifluoromethoxy-benzyl)-2,3 -dihydro-isoindol- 1 -one in the presence of zinc cyanide, l,l '-bis(diphenylphospino)ferrocene and
tris(dibenzylideneacetone)-dipalladium in an organic solvent to form 7-methyl-l-oxo-2-(4- trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5-carbonitrile;
hydrolysis of 7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-
5- carbonitrile in a solvent with a hydroxide solution to form 7-methyl-l-oxo-2-(4- trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5-carboxylic acid; reacting 7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5- carboxylic acid in an organic solvent with thionyl chloride or another chlorinating agent and reacting the product with tert-butyl 4-[(2Z)-2-amino-2-hydroxyimino)ethyl]-piperazine-l- carboxylate in the presence of a base to form 4-{5-[7-methyl-l-oxo-2-(4-trifluoromethoxy- benzyl)-2,3-dihydro-lH-isoindol-5-yl]-[l,2,4]oxadiazol-3-ylmethyl}-piperazine-l-carboxylic acid tert-butyl ester, and
decarboxylating 4-{5-[7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH- isoindol-5-yl]-[l,2,4]oxadiazol-3-ylmethyl}-piperazine-l-carboxylic acid tert-butyl ester by heating with acid in a solvent, to form 7-methyl-5-(3-piperazin-l-ylmethyl-[l,2,4]oxadiazol-5- yl)-2-(4-trifluoromethoxy-benzyl)-2,3 -dihydro-isoindol- 1 -one or an acid salt thereof.
Claim 2 A process for preparing 7-methyl-5-(3-piperazin- 1 -ylmethyl-[ 1 ,2,4]oxadiazol-5- yl)-2-(4-trifluoromethoxybenzyl -2,3-dihydroisoindol-l-one, having the structure below:
Figure imgf000018_0001
or an acid salt thereof, the process comprising:
reacting tert-butyl piperazine-l-carboxylate with bromoacetonitrile, in an organic solvent in the presence of a base and subsequent reaction with hydroxylamine or an acid salt thereof to form 4-(N-hydroxycarbamimidoylmethyl)-piperazine-l-carboxylic acid tert-butyl ester;
formylating ethyl-3-furoate with a Vilsmeier reagent formed by reaction of phosphoryl chloride with dimethylformamide or another formylating agent to form 5-formyl-furan-3- carboxylic acid ethyl ester;
reacting 5-formyl-furan-3-carboxylic acid ethyl ester in an organic solvent with
4-(trifluoromethoxy)-benzylamine and reducing the product to form 5-[(4-trifluoromethoxy- benzylamino)-methyl]-furan-3-carboxylic acid ethyl ester or an acid salt thereof ;
reacting 5-[(4-trifluoromethoxy-benzylamino)-methyl]-furan-3-carboxylic acid ethyl ester or an acid salt thereof with crotonoyl chloride in the presence of a base, with subsequent heating or other conditions so as to affect a Diels Alder transformation and subsequent dehydration of the product with an acid or base to form 7-methyl-l-oxo-2-(4-trifluoromethoxy- benzyl)-2,3-dihydro-lH-isoindole-5-carboxylic acid ethyl ester;
reacting 7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5- carboxylic acid ethyl ester with tert-butyl 4-[(2Z)-2-amino-2-hydroxyimino)ethyl]-piperazine-l- carboxylate in an organic solvent with a base to form 4-{5-[7-methyl-l-oxo-2-(4- trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindol-5-yl]-[l,2,4]oxadiazol-3-ylmethyl}- piperazine-1 -carboxylic acid tert-butyl ester, and
decarboxylating 4-{5-[7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH- isoindol-5-yl]-[l,2,4]oxadiazol-3-ylmethyl}-piperazine-l -carboxylic acid tert-butyl ester by heating with acid in an organic solvent, to form 7-methyl-5-(3-piperazin-l-ylmethyl-
[l,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-isoindol-l-one or an acid salt thereof.
Claim 3 A compound selected from the group consisting of:
5-bromo-7-methyl-3H-isobenzofuran- 1 -one;
4- bromo-2-hydroxymethyl-6-methyl-N-(4-trifluoromethoxy-benzyl)-benzamide;
5 - [(4-trifluoromethoxy-benzylamino)-methyl]-furan-3 -carboxylic acid or an alkyl ester thereof, and
7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-lH-isoindole-5-carboxylic acid or an alkyl ester thereof.
Claim 4 A process for making 5-bromo-7-methyl-3H-isobenzofuran- 1 -one,
Figure imgf000019_0001
the process comprising:
reacting 5 -bromo-2-iodo- 1,3 -dimethyl-benzene in an ether solvent with a Grignard reagent and carbon dioxide gas to form 4-bromo-2,6-dimethylbenzoic acid, and heating 4-bromo-2,6-dimethylbenzoic acid with N-bromosuccinimide and a radical initiator in an organic solvent and subsequent reduction of over-brominated products with a reducing agent to form 5-bromo-7-methyl-3H-isobenzofuran-l-one. Claim 5 A process for making 4-bromo-2-hydroxymethyl-6-methyl-N-(4- trifluoromethoxy-benzyl)-benzamide,
Figure imgf000020_0001
the process comprising:
reacting tert-butyl piperazine-l-carboxylate with bromoacetonitrile, in an organic solvent in the presence of a base and subsequent reaction with hydroxylamine or an acid salt thereof to form 4-(N-hydroxycarbamimidoylmethyl)-piperazine-l-carboxylic acid tert-butyl ester;
reacting 5 -bromo-2-iodo- 1,3 -dimethyl-benzene in an ether solvent with a Grignard reagent and carbon dioxide gas to form 4-bromo-2,6-dimethylbenzoic acid;
heating 4-bromo-2,6-dimethylbenzoic acid with N-bromosuccinimide and a radical initiator in an organic solvent and subsequent reduction of over-brominated products with a reducing agent to form 5-bromo-7-methyl-3H-isobenzofuran-l-one;
heating 5-bromo-7-methyl-3H-isobenzofuran-l-one with
4-(trifluoromethoxy)-benzylamine in an anhydrous solvent with trimethylaluminium to form 4- bromo-2-hydroxymethyl-6-methyl-N-(4-trifluoromethoxy-benzyl)-benzamide.
Claim 6 A process for making 5-[(4-trifluoromethoxy-benzylamino)-methyl]-furan-3- carboxylic acid ethyl ester or an acid salt thereof,
Figure imgf000020_0002
the process comprising:
reacting tert-butyl piperazine-l-carboxylate with bromoacetonitrile, in an organic solvent in the presence of a base and subsequent reaction with hydroxylamine or an acid salt thereof to form 4-(N-hydroxycarbamimidoylmethyl)-piperazine-l-carboxylic acid tert-butyl ester;
formylating ethyl-3-furoate with a Vilsmeier reagent formed by reaction of phosphoryl chloride with dimethylformamide or another formylating agent to form 5-formyl-furan-3- carboxylic acid ethyl ester;
reacting 5-formyl-furan-3-carboxylic acid ethyl ester in an organic solvent with
4-(trifluoromethoxy)-benzylamine and reducing the product to form 5-[(4-trifluoromethoxy- benzylamino)-methyl]-furan-3-carboxylic acid ethyl ester.
Claim 7 A process for making 7-methyl-l-oxo-2-(4-trifluoromethoxy-benzyl)-2,3- dihydro-lH-isoindole-5-carbox lic acid ethyl ester,
Figure imgf000021_0001
the process comprising:
reacting tert-butyl piperazine-l-carboxylate with bromoacetonitrile, in an organic solvent in the presence of a base and subsequent reaction with hydroxylamine or an acid salt thereof to form 4-(N-hydroxycarbamimidoylmethyl)-piperazine-l-carboxylic acid tert-butyl ester;
formylating ethyl-3-furoate with a Vilsmeier reagent formed by reaction of phosphoryl chloride with dimethylformamide or another formylating agent to form 5-formyl-furan-3- carboxylic acid ethyl ester;
reacting 5-formyl-furan-3-carboxylic acid ethyl ester in an organic solvent with
4-(trifluoromethoxy)-benzylamine and reducing the product to form 5-[(4-trifluoromethoxy- benzylamino)-methyl]-furan-3-carboxylic acid ethyl ester or an acid salt thereof;
reacting 5-[(4-trifluoromethoxy-benzylamino)-methyl]-furan-3-carboxylic acid ethyl ester or an acid salt thereof with crotonoyl chloride in the presence of a base, with subsequent heating or other conditions so as to affect a Diels Alder transformation and subsequent dehydration of the product with an acid or base to form 7-methyl-l-oxo-2-(4-trifluoromethoxy- benzyl)-2,3-dihydro-lH-isoindole-5-carboxylic acid ethyl ester.
PCT/SE2011/050002 2010-01-07 2011-01-04 Process for making a metabotropic glutamate receptor positive allosteric modulator - 874 WO2011084098A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SG2012047528A SG181958A1 (en) 2010-01-07 2011-01-04 Process for making a metabotropic glutamate receptor positive allosteric modulator - 874
BRBR112012016786-3A BR112012016786A2 (en) 2010-01-07 2011-01-04 Processes for preparing 7-methyl-5- (3-piperazin-1-ylmethyl- [1,2,4] oxadiazol-5-yl) -2- (4-trifluoromethoxybenzyl) -2
US13/519,398 US20130203995A1 (en) 2010-01-07 2011-01-04 Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874
AU2011203993A AU2011203993A1 (en) 2010-01-07 2011-01-04 Process for making a metabotropic glutamate receptor positive allosteric modulator - 874
EP20110731990 EP2521722B1 (en) 2010-01-07 2011-01-04 Process for making a metabotropic glutamate receptor positive allosteric modulator - 874
MX2012007992A MX2012007992A (en) 2010-01-07 2011-01-04 Process for making a metabotropic glutamate receptor positive allosteric modulator - 874.
DK11731990.5T DK2521722T3 (en) 2010-01-07 2011-01-04 PROCEDURE FOR THE PREPARATION OF A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874
CN2011800128476A CN102791706A (en) 2010-01-07 2011-01-04 Process for making a metabotropic glutamate receptor positive allosteric modulator-874
CA2786327A CA2786327A1 (en) 2010-01-07 2011-01-04 Process for making a metabotropic glutamate receptor positive allosteric modulator - 874
JP2012547983A JP2013516462A (en) 2010-01-07 2011-01-04 Method for producing metabotropic glutamate receptor positive allosteric modulator-874
RU2012134329/04A RU2012134329A (en) 2010-01-07 2011-01-04 METHOD FOR PRODUCING A POSITIVE ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS-874
IL220683A IL220683A0 (en) 2010-01-07 2012-06-28 Process for making a metabotropic glutamate receptor positive allosteric modulator-874

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29301210P 2010-01-07 2010-01-07
US61/293,012 2010-01-07

Publications (1)

Publication Number Publication Date
WO2011084098A1 true WO2011084098A1 (en) 2011-07-14

Family

ID=44305652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2011/050002 WO2011084098A1 (en) 2010-01-07 2011-01-04 Process for making a metabotropic glutamate receptor positive allosteric modulator - 874

Country Status (14)

Country Link
US (1) US20130203995A1 (en)
EP (1) EP2521722B1 (en)
JP (1) JP2013516462A (en)
KR (1) KR20120112749A (en)
CN (1) CN102791706A (en)
AU (1) AU2011203993A1 (en)
BR (1) BR112012016786A2 (en)
CA (1) CA2786327A1 (en)
DK (1) DK2521722T3 (en)
IL (1) IL220683A0 (en)
MX (1) MX2012007992A (en)
RU (1) RU2012134329A (en)
SG (1) SG181958A1 (en)
WO (1) WO2011084098A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2563782A1 (en) * 2010-04-30 2013-03-06 AstraZeneca AB Polymorphs of a metabotropic glutamate receptor positive allosteric modulator
US9657041B2 (en) 2013-12-31 2017-05-23 Chemapotheca, Llc Chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursors having a regioisomeric purity >99%
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US11717498B2 (en) 2013-12-31 2023-08-08 Pharmapotheca A, Inc. Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms
US12006275B2 (en) 2019-03-02 2024-06-11 Pharmapotheca A, Inc. Process for making levoamphetamine

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107935842A (en) * 2017-12-27 2018-04-20 珠海奥博凯生物医药技术有限公司 A kind of preparation method of 2 chlorine, 4 bromine, 6 methyl benzoic acid
CN110498783A (en) * 2019-08-02 2019-11-26 成都蓝蜻蜓生物技术有限公司 A method of his intermediate of synthesis Luo Shasi

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020879A1 (en) * 2004-08-13 2006-02-23 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2008150232A1 (en) 2007-06-07 2008-12-11 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators - 841
WO2008150233A1 (en) 2007-06-07 2008-12-11 Astrazeneca Ab Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842
US20090111830A1 (en) * 2005-08-12 2009-04-30 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261934T1 (en) * 1998-12-16 2004-04-15 Boehringer Ingelheim Pharma SUBSTITUTED ARYL AND HETEROARYLAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
WO2007021308A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020879A1 (en) * 2004-08-13 2006-02-23 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20090111830A1 (en) * 2005-08-12 2009-04-30 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
WO2008150232A1 (en) 2007-06-07 2008-12-11 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators - 841
WO2008150233A1 (en) 2007-06-07 2008-12-11 Astrazeneca Ab Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BORDI; UGOLINI, BRAIN RES., vol. 871, 1999, pages 223
KNOPFEL, J. MED. CHEM., vol. 38, 1995, pages 1417
MELLER ET AL., NEUROREPORT, vol. 4, 1993, pages 879
NAKANISHI, NEURON, vol. 13, 1994, pages 1031
PIN ET AL., NEUROPHARMACOLOGY, 1995
SAFDAR HAYAT ET AL.: "An improved method for the synthesis of [gamma]- lactones using sodium bromate and sodium hydrogen sulfite", TETRAHEDRON LETTERS, vol. 42, no. 9, 1 February 2001 (2001-02-01), pages 1647 - 1649
See also references of EP2521722A4

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2563782A1 (en) * 2010-04-30 2013-03-06 AstraZeneca AB Polymorphs of a metabotropic glutamate receptor positive allosteric modulator
EP2563782A4 (en) * 2010-04-30 2013-09-04 Astrazeneca Ab Polymorphs of a metabotropic glutamate receptor positive allosteric modulator
US9657041B2 (en) 2013-12-31 2017-05-23 Chemapotheca, Llc Chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursors having a regioisomeric purity >99%
US11717498B2 (en) 2013-12-31 2023-08-08 Pharmapotheca A, Inc. Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US12006320B2 (en) 2018-11-13 2024-06-11 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US12006275B2 (en) 2019-03-02 2024-06-11 Pharmapotheca A, Inc. Process for making levoamphetamine

Also Published As

Publication number Publication date
CA2786327A1 (en) 2011-07-14
RU2012134329A (en) 2014-02-20
KR20120112749A (en) 2012-10-11
JP2013516462A (en) 2013-05-13
DK2521722T3 (en) 2015-07-20
US20130203995A1 (en) 2013-08-08
AU2011203993A1 (en) 2012-08-02
EP2521722A4 (en) 2013-05-29
SG181958A1 (en) 2012-07-30
EP2521722B1 (en) 2015-05-06
EP2521722A1 (en) 2012-11-14
IL220683A0 (en) 2012-08-30
MX2012007992A (en) 2012-08-03
CN102791706A (en) 2012-11-21
BR112012016786A2 (en) 2015-09-01

Similar Documents

Publication Publication Date Title
EP2521722B1 (en) Process for making a metabotropic glutamate receptor positive allosteric modulator - 874
US20230303489A1 (en) Compounds, compositions and methods of use
TWI477499B (en) Metabotropic glutamate receptor isoxazole ligands and their use as potentiators-286
EP3433234A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
CA2718727A1 (en) Heterocyclic compound
JP6581745B2 (en) Pyrazole-oxazolidinone compound of anti-hepatitis B virus
EA014956B1 (en) Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
TW200821305A (en) MGluR5 modulators
TW200800211A (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
CN101679272B (en) Triazolo [1, 5-a] quinolines as adenosine A3 receptor ligands
WO2018181345A1 (en) Heterocyclic compound
TW201418225A (en) Imidazole derivatives
DK162985B (en) PYRIDAZINE DERIVATIVES SUBSTITUTED WITH AMINO IN THE 3-POSITION, AND AFFECTING THE CENTRAL NERVOUS SYSTEM, PROCEDURES FOR THE MANUFACTURING THEREOF AND MEDICINAL PRODUCTS CONTAINING THEREOF
TW201022283A (en) Fused imidazole carboxamides as TRPV3 modulators
CN101983197B (en) A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
HU190377B (en) Process for preparing theophyllinyl-alkyl-oxadiazoles
KR20080065674A (en) Novel indole-containing beta agonists, method for producing them and their use as drugs
EP3684357A1 (en) Heteroaryl allosteric modulators of nicotinic acetylcholine receptors
JP2750869B2 (en) Tricyclic fused pyrimidine derivatives
WO2023077049A1 (en) Methods of preparing 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds
CN112457265A (en) Tetrazole derivative, preparation method thereof, pharmaceutical composition containing tetrazole derivative and application of pharmaceutical composition
WO2004089939A1 (en) Condensed furan derivatives as adenosine antagonists
JP2024540608A (en) Heterocyclic substituted 1,3,4-thiadiazole and pyridazine compounds and methods of use thereof - Patents.com
CN117088861A (en) 2-substituted aryl-oxazolin-4-one derivative and application thereof
NZ785933A (en) Allosteric modulators of nicotinic acetylcholine receptors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180012847.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11731990

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 220683

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2786327

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 5941/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2012547983

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/007992

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011203993

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2011731990

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011203993

Country of ref document: AU

Date of ref document: 20110104

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127020581

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012134329

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 13519398

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012016786

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012016786

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120706